IOVANCE BIOTHERAPEUTICS, INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $2.29 million for the 72-month period ending 2013-12-31, per its 10-K filed 2014-03-28.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2014-03-28
- IOVANCE BIOTHERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2012-12-31 was $1.14M, a 557.92% increase year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2012-09-30 was $741.99K, a 587.85% increase year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2012-06-30 was $327.88K, a 463.90% increase year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2012-03-31 was $372.18K, a 781.92% increase year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2013 was -$543.56K, a 121.06% decline from fiscal 2012.
- IOVANCE BIOTHERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2012 was $2.58M, a 576.84% increase from fiscal 2011.
- IOVANCE BIOTHERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2011 was $381.26K, a 1158.63% increase from fiscal 2010.
- IOVANCE BIOTHERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2010 was $30.29K.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 45 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 48 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 51 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 54 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 57 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 60 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 72 month |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2013-12-31 | -$543.56K 10-K · filed 2014-03-28 | $2.29M 10-K · filed 2014-03-28 | |||||||||
| 2012-12-31 | $1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-28 | $1.88M derived: sum of 2 quarters · filed 2014-03-28 | $2.21M derived: sum of 3 quarters · filed 2014-03-28 | $2.58M 10-K · filed 2014-03-28 | |||||||
| 2012-09-30 | $741.99K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2013-01-25 | $1.07M derived: sum of 2 quarters · filed 2013-01-25 | $1.44M 10-Q · filed 2013-01-25 | $1.62M derived: sum of 4 quarters · filed 2013-01-25 | $1.85M 10-Q · filed 2013-01-25 | ||||||
| 2012-06-30 | $327.88K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2012-09-10 | $700.06K 10-Q/A · filed 2012-09-10 | $873.11K derived: sum of 3 quarters · filed 2012-09-10 | $980.98K derived: sum of 4 quarters · filed 2013-01-25 | $1.11M 10-Q/A · filed 2012-09-10 | ||||||
| 2012-03-31 | $372.18K 10-Q · filed 2012-05-15 | $545.22K derived: sum of 2 quarters · filed 2012-05-15 | $653.09K derived: sum of 3 quarters · filed 2013-01-25 | $711.24K derived: sum of 4 quarters · filed 2013-01-25 | $783.73K 10-Q · filed 2012-05-15 | ||||||
| 2011-12-31 | $173.05K derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-30 | $280.92K derived: sum of 2 quarters · filed 2013-01-25 | $339.06K derived: sum of 3 quarters · filed 2013-01-25 | $381.26K 10-K · filed 2012-03-30 | $411.56K 10-K · filed 2012-03-30 | ||||||
| 2011-09-30 | $107.87K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2013-01-25 | $166.01K derived: sum of 2 quarters · filed 2013-01-25 | $208.22K 10-Q · filed 2013-01-25 | $213.02K derived: sum of 4 quarters · filed 2013-01-25 | $238.51K 10-Q · filed 2011-11-21 | ||||||
| 2011-06-30 | $58.15K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2012-09-10 | $100.35K 10-Q/A · filed 2012-09-10 | $105.15K derived: sum of 3 quarters · filed 2012-09-10 | $114.86K derived: sum of 4 quarters · filed 2012-09-10 | $130.64K 10-Q/A · filed 2011-09-01 | ||||||
| 2011-03-31 | $42.20K 10-Q · filed 2012-05-15 | $47.00K derived: sum of 2 quarters · filed 2012-05-15 | $56.72K derived: sum of 3 quarters · filed 2012-05-15 | ||||||||
| 2010-12-31 | $4.80K derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-30 | $14.52K derived: sum of 2 quarters · filed 2012-03-30 | $30.29K 10-K · filed 2012-03-30 | ||||||||
| 2010-09-30 | $9.71K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2011-11-21 | $25.49K 10-Q · filed 2011-11-21 | |||||||||
| 2010-06-30 | $15.78K 10-Q/A · filed 2011-09-01 | ||||||||||
| 2009-12-31 | -$8.00 10-K · filed 2012-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |